Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18005446 | 0.91 | ESR1 (0.32) | MET | |
| SCHEMBL18005360 | 0.87 | KDM4E (0.41) | ALOX15NOTUMCNR2 | |
| SCHEMBL18005334 | 0.86 | ALOX15 (0.37) | ALOX15GRM5METNOTUMTGFBR1 | |
| SCHEMBL18005255 | 0.84 | MAPK14 (0.36) | ALOX15GRM5METNOTUMTGFBR1 | |
| SCHEMBL18005399 | 0.84 | ALOX15 (0.35) | ALOX15GRM5METNOTUMTGFBR1 | |
| SCHEMBL18005500 | 0.84 | GRM5 (0.36) | ALOX15GRM5METNOTUMTGFBR1 | |
| SCHEMBL18005324 | 0.83 | ALOX15 (0.34) | ALOX15GRM5METNOTUMTGFBR1 | |
| SCHEMBL18005330 | 0.82 | MET (0.35) | ALOX15GRM5METNOTUMTGFBR1 | |
| SCHEMBL18005291 | 0.81 | GRM5 (0.43) | ALOX15GRM5METTGFBR1TGFBR2 | |
| SCHEMBL18005488 | 0.80 | NOTUM (0.41) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | ALOX15 2623/4885GRM5 1425/4885MET 1844/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | ALOX15 2623/4885GRM5 1425/4885MET 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.